Our Projects

• SP1: Understanding and exploiting molecular and cellular reprogramming in response to EZH2 inhibition in PDAC

• SP2: Characterizing subtype-specific adaptation to epigenetic therapy in PDAC

• SP3: Characterization of the epigenomic landscape that contributes to adaptation to molecular therapies in HCC

• SP4: Exploring ER stress-induced metabolic adaptation in the treatment of PDAC

• SP5: Understanding and exploiting adaptation to asparagine deprivation in GI cancer

• SP6: Investigating adaptation of rectal cancer to neoadjuvant therapy

• SP7: Understanding and exploiting tumor cell specific adaptations to targeted therapies in BTC

• SP8: Dissecting the influence of an intact immune system on the DTP state under targeted therapies in biliary tract cancer

• SP9: Dissecting adaptation of the tumor microenvironment upon targeting of mutp53 subtypes in colorectal and pancreatic cancer

• SP10: Dissecting adaptation of the microbiome and the immune environment in BTC and PDAC upon systemic therapies

• SP11: Elucidating and targeting of vessel co-option as adaptation under anti-angiogenic therapy for colorectal cancer

• SP12: Identification of predictive biomarkers of systemic immune cell adaptation in patients undergoing locoregional or surgical HCC therapy